Ovarian Cancer News & Features
Women who have ovarian cancer often develop ascites, a buildup of fluids in the abdomen. Researchers have found that ascites can be reduced with minimal side effects through inhibition of the colony-stimulating-factor-1 receptor (CSF1R).
The protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in patients with breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
The more children a woman has or whether she has undergone tubal ligation lowers her risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 NCRI Cancer Conference.
A healthy diet may reduce the risk for developing ovarian cancer in African American women.
Patients who develop ovarian cancer may have improved outcomes if they have prior oral contraceptive use.
Ovarian Cancer Clinical Trials
- Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme
- New Blood Test Improves Screening for Prostate Cancer
- Nanoliposomal Irinotecan Extends Survival in Metastatic Pancreatic Cancer
- S-1 as First-line Chemo for HER2- Metastatic Breast Cancer
- Blood Sample Offers a New Way of Detecting Cancer
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
- Rates of PSA Screening and Early Stage Prostate Cancer Are Declining
- Use of Genomic Testing in Breast Cancer Has Greater Impact on Treatment, Costs
- Timing Matters for Pegfilgrastim Administration
- Estrogen Plus Progestin Use Increases ER+ Breast Cancer Risk in African American Women
- CSF1R Inhibition May Ease Debilitating Adverse Event of Ovarian Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|